Parathyroid hormone 7-34

Drug Profile

Parathyroid hormone 7-34

Alternative Names: Parathyroid hormone 7-34 - IGI; PTH (7-34); PTH 7-34; PTHrP (7-34)

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator IGI
  • Developer Boston University; Teligent
  • Class Chemoprotectants; Peptide fragments; Peptide hormones
  • Mechanism of Action Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Alopecia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alopecia in USA (Topical, Cream)
  • 09 May 2007 IGI receives STTR grant from the US National Cancer Institute for development of PTH 7-34 in chemotherapy-induced Alopecia
  • 13 Dec 2005 IGI has extended its exclusive license from Novavax for the use of Novasome® lipid vesicle encapsulation technology, micellar nanoparticles, and the Ultrasponge® Technology until December 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top